Amgen successfully raised approximately $3.96 billion through a multi-tranche senior unsecured notes offering on February 17, 2026. The notes, maturing between 2031 and 2056 with varying coupons, include investor protections such as a change-of-control provision. Amgen stock is currently rated as a Hold by analysts with a $375 price target, while TipRanks’ AI Analyst, Spark, rates it as Outperform, citing strong technical strength and supportive earnings outlook despite financial risks from leverage.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Amgen Prices $4 Billion Senior Unsecured Notes Offering
Amgen successfully raised approximately $3.96 billion through a multi-tranche senior unsecured notes offering on February 17, 2026. The notes, maturing between 2031 and 2056 with varying coupons, include investor protections such as a change-of-control provision. Amgen stock is currently rated as a Hold by analysts with a $375 price target, while TipRanks’ AI Analyst, Spark, rates it as Outperform, citing strong technical strength and supportive earnings outlook despite financial risks from leverage.